The increasing growth of government support for pharmaceutical and biotechnology industries, rising R&D activities in life sciences research, and rising cell culture contamination are expected to drive the growth of this market.
The global market is segmented by product, technique, application, end user, and region. By product, the market is segmented into kits & reagent, services, and instruments. The kits & reagent segment is expected to lead the global mycoplasma testing market in 2017. The frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques are the key factors driving the growth of this segment.
Based on technique, the market is classified into PCR, ELISA, direct assays, indirect assays, DNA staining, microbial culture techniques, and enzymatic methods. The PCR segment is expected to account for the largest share of the market in 2017 due it the high acceptance rate of PCR, which can be attributed to its accuracy, speed, and flexibility in life sciences research.
Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, end-of-production cell testing, and other applications. Cell line testing segment accounts for the largest segment and is also the fastest growing application segment in the market. Increasing use of cell lines for research and biopharmaceutical production is the major factor driving the growth of this market.
The global mycoplasma testing market is dominated by North America, followed by Europe. North America will continue to dominate the global market during the forecast period. However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China, Japan, and India. The increase in generics development and manufacturing is a major growth driver for the pharmaceutical industry in this region. Growing government investments in pharmaceutical R&D and the increasing trend of pharmaceutical outsourcing are some factors propelling market growth in the Asian region.
Sample Report – https://www.marketsandmarkets.com/requestsampleNew.asp?id=136509856
Key Players:
The key players in the mycoplasma testing market include Thermo Fisher Scientific Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), SGS S.A. (Switzerland), American Type Culture Collection (U.S.), Bionique Testing Laboratories, Inc. (U.S.), InvivoGen (U.S.), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd., WuXi AppTec (U.S.), Norgen Biotek Corp. (Canada), Agilent Technologies (U.S.), Biotools, B & M Labs, S.A (Spain), Eurofins Scientific (Luxembourg), Gibraltar Laboratories (U.S.), GeneCopoeia, Inc. (U.S.), GenBio (Canada), Hylabs (Israel), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (U.S.), Sartorius AG (Germany), Savyon Diagnostics (Israel), and ScienCell Research Laboratories, Inc. (Canada).
